| 前收市價 | 85.35 |
| 開市 | 無 |
| 買盤 | 62.00 |
| 賣出價 | 63.65 |
| 拍板 | 215.00 |
| 到期日 | 2024-07-19 |
| 今日波幅 | 85.35 - 85.35 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 13 |
Investor's Business DailyDow Jones Biotech Amgen, Netflix, Robinhood, Spotify In Bullish Chart Setups
Dow Jones biotech leader Amgen, along with streaming giant Netflix and Spotify, are in or near buy zones in today's stock market.
Motley FoolThe Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
There's probably a big enough pie here for everyone to get a slice.
BenzingaAmgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi
